Belite Bio, Inc Belite Bio, Inc

Belite Bio, Inc

BLTE

Hisse Senetlerindeki Sıralama #3148
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Hisse Fiyatı
$143.80
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$5.74B
Değişim (1 gün)
-5.78%
Değişim (1 yıl)
63.95%
Ülke
US
Ticaret Belite Bio, Inc (BLTE)

Kategori

Healthcare
Belite Bio, Inc (BLTE) için EPS
June 2026 itibariyle EPS TTM: $-2.76
Belite Bio, Inc şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) $-2.76'dir. 2023 yılı sonunda, şirketin EPS'si $-1.19 idi; bu, 2022 yılındaki EPS olan $-0.63 ile önceki yıla göre artış.
Belite Bio, Inc için 2020 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
Yıl EPS Değiştir
2026 (TTM) $-2.76 133.90%
2024 $-1.18 -0.84%
2023 $-1.19 88.89%
2022 $-0.63 57.50%
2021 $-0.40 -35.48%
2020 $-0.62 0.00%
Benzer şirketler veya rakipler için EPS
Şirket EPS EPS Farkı Ülke
$17.32 -727.54%
US
$-7.98 189.13%
US
$-5.29 91.67%
AU
- -
CH
$27.74 -1,105.07%
NL